Hostname: page-component-848d4c4894-ttngx Total loading time: 0 Render date: 2024-06-08T15:06:10.340Z Has data issue: false hasContentIssue false
  • English
  • Français

Divergence of dose–response with asenapine: a cluster analysis of randomized, double-blind, and placebo control study

Published online by Cambridge University Press:  19 January 2021

Yoshiteru Takekita Open the ORCID record for Yoshiteru Takekita [Opens in a new window] ,
Shuichi Hiraoka ,
Yasuhiro Iwama ,
Naotaka Sunada ,
Nobuatsu Aoki ,
Haruhiko Ogata ,
Toshiya Funatsuki ,
Chikashi Takano ,
Tomoyo Yanagida  and
Yosuke Koshikawa
...Show all authors
Yoshiteru Takekita*
Affiliation:
Department of Neuropsychiatry, Kansai Medical University, Osaka, Japan
Shuichi Hiraoka
Affiliation:
Medical Science Section, Pharmaceutical Research & Development Division, Meiji Seika Pharma Co., Ltd., Tokyo, Japan
Yasuhiro Iwama
Affiliation:
Regulatory & Datascience Department, Pharmaceutical Research & Development Division, Meiji Seika Pharma Co., Ltd., Tokyo, Japan
Naotaka Sunada
Affiliation:
Department of Neuropsychiatry, Kansai Medical University, Osaka, Japan
Nobuatsu Aoki
Affiliation:
Department of Neuropsychiatry, Kansai Medical University, Osaka, Japan
Haruhiko Ogata
Affiliation:
Department of Neuropsychiatry, Kansai Medical University, Osaka, Japan
Toshiya Funatsuki
Affiliation:
Department of Neuropsychiatry, Kansai Medical University, Osaka, Japan
Chikashi Takano
Affiliation:
Department of Neuropsychiatry, Kansai Medical University, Osaka, Japan
Tomoyo Yanagida
Affiliation:
Department of Neuropsychiatry, Kansai Medical University, Osaka, Japan
Yosuke Koshikawa
Affiliation:
Department of Neuropsychiatry, Kansai Medical University, Osaka, Japan
Minami Naito
Affiliation:
Department of Neuropsychiatry, Kansai Medical University, Osaka, Japan
Atsuko Yamamoto
Affiliation:
Department of Neuropsychiatry, Kansai Medical University, Osaka, Japan
Masaki Kato
Affiliation:
Department of Neuropsychiatry, Kansai Medical University, Osaka, Japan
Toshihiko Kinoshita
Affiliation:
Department of Neuropsychiatry, Kansai Medical University, Osaka, Japan
*
*Author for correspondence: Yoshiteru Takekita Email: takekity@takii.kmu.ac.jp
Get access Rights & Permissions [Opens in a new window]

Abstract

Background

Differences in psychiatric background and dose–response to asenapine in patients with schizophrenia were examined based on efficacy and safety, using data obtained in a double-blind, placebo-controlled trial.

Methods

Patients with schizophrenia were classified into three clusters by a cluster analysis based on the Positive and Negative Symptom Scale (PANSS) subscores at baseline, using the data from a 6-week, double-blind, placebo-controlled trial. PANSS Marder factor scores were calculated for each cluster. The efficacy of 10 or 20 mg/day of asenapine on PANSS score was used as the primary endpoint, with the incidence of adverse events evaluated as the secondary endpoint.

Results

A total of 529 asenapine-treated patients were classified into 3 clusters: Cluster-P with the higher scores in positive symptoms, disorganized thoughts, and hostility/excitement, Cluster-N with higher scores in negative symptoms, and Cluster-L with overall lower scores. In Cluster-N and Cluster-L, both 10 and 20 mg/day groups showed significant improvement in PANSS scores, while only the 20 mg/day group showed a significant difference in Cluster-P. Cluster-N and Cluster-L had differences in the incidence of adverse events, but this was not seen in Cluster-P.

Conclusions

The efficacy and safety of asenapine 10 and 20 mg/day differed between the 3 clusters of patients. This suggests that background information regarding baseline psychiatric symptoms may affect the therapeutic response in patients with schizophrenia.

Keywords

Antipsychoticasenapinecluster analysisdose responseschizophrenia
Type
Original Research
Information
CNS Spectrums , Volume 27 , Issue 3 , June 2022 , pp. 369 - 377
Copyright
© The Author(s), 2021. Published by Cambridge University Press

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Leheman, AF, Lieberman, JA, Dixon, LB, et al. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry. 2004;161(Suppl 2):1–56.Google Scholar
Barnes, TR, Drake, R, Paton, C, et al. Evidence-based guidelines for the pharmacological treatment of schizophrenia: updated recommendations from the British association for psychopharmacology. J Psychopharmacol. 2020;34(1):3–78.CrossRefGoogle ScholarPubMed
Hasan, A, Wobrock, PFT, Lieberman, J, et al. World federation of societies of biological psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. World J Biol Psychiatry. 2012;13:318–378.CrossRefGoogle ScholarPubMed
NICE. Psychosis and schizophrenia in adults: treatment and management. NICE clinical guideline 178. London, UK: National Institute for Health and Care Excellence; 2014. https://www.ncbi.nlm.nih.gov/books/NBK248060/pdf/Bookshelf_NBK248060.pdf Google Scholar
Samara, MT, Klupp, E, Helfer, B, et al. Increasing antipsychotic dose for nonresponse in schizophrenia. Cochrane Database Syst Rev. 2018;5(5):CD011883. doi:10.1002/14651858.Google Scholar
Sakurai, H, Suzuki, T, Bies, RR, et al. Increasing versus maintaining the dose of olanzapine or risperidone in schizophrenia patients who did not respond to a modest dosage: A double-blind randomized controlled trial. J Clin Psychiatry. 2016;77(10):1381–1390.CrossRefGoogle Scholar
Buchanan, RW, Carpenter, WT. Clinically meaningful gaps between clinical trial and patient treatment. Schizophr Bull. 2018;44(4):701–702.CrossRefGoogle ScholarPubMed
Hui, CLM, Lam, BST, Lee, EHM, et al. A systemic review of clinical guidelines on choice, dose, and duration of antipsychotics treatment in first- and multi-episode schizophrenia. Int Rev Psychiatry. 2019;31(5–6):441–459.CrossRefGoogle Scholar
Takeuchi, H, MacKenzie, NE, Samaroo, D, et al. Antipsychotic Dose in Acute Schizophrenia: A Meta-analysis. Schizophr Bull. 2020;46(6):1439–1458.CrossRefGoogle Scholar
Someya, T, Muratake, T, Hirokane, G, et al. Interindividual variation in bromperidol metabolism and relationship to therapeutic effects. J Clin Psychopharmacol. 2000;20(2):175–180.CrossRefGoogle ScholarPubMed
Kapur, S, Zipursky, R, Roy, P, et al. The relationship between D2 receptor occupancy and plasma levels on low dose oral haloperidol: a PET study. Psychopharmacology. 1997;131:148–152.CrossRefGoogle ScholarPubMed
Kinon, BJ, Volavka, J, Stauffer, V, et al. Standard and higher dose of olanzapine in patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, fixed-dose study. J Clin Psychopharmacol. 2008;28(4):392–400.CrossRefGoogle ScholarPubMed
Nagino, K, Koh, T, Harada, Y. Pharmacological properties of paliperidone ER (INVEGA®) and results of its clinical studies. Folia Pharmacol Jpn. 2011;137:245–254.CrossRefGoogle ScholarPubMed
Kinoshita, T, Bai, YM, Kim, JH, et al. Efficacy and safety of asenapine in asian patients with an acute exacerbation of schizophrenia: a multicenter, randomized, double-blind, 6-week, placebo-controlled study. Psychopharmacology. 2016;233:2663–2674.CrossRefGoogle ScholarPubMed
Iwata, N, Ishigooka, J, Kim, WH, et al. Efficacy and safety of blonanserin transdermal patch in patients with schizophrenia: a 6-week randomized, double-blind, placebo-controlled, multicenter study. Schizophr Res. 2020;215:408–415.CrossRefGoogle ScholarPubMed
Leucht, S, Crippa, A, Siafis, S, et al. Dose-response meta-analysis of antipsychotic drugs for acute schizophrenia. Am J Psychiatry. 2020;177(4):342–353.CrossRefGoogle ScholarPubMed
Howes, OD, Kapur, S. A neurobiological hypothesis for the classification of schizophrenia: Type a (hyperdopaminergic) and type b (normodopaminergic). Br J Psychiatry. 2014;205(1):1–3.CrossRefGoogle Scholar
Crow, TJ. The two-syndrome concept: origins and current status. Schizophr Bull. 1985;11(3):471–486.CrossRefGoogle ScholarPubMed
Carbon, M, Correll, CU. Clinical predictors of therapeutic response to antipsychotics in schizophrenia. Dialogues Clin Neurosci. 2014;16(4):505–524.CrossRefGoogle Scholar
Inada, T. DIEPSS: A Second-Generation Rating Scale for Antipsychotic-Induced Extrapyramidal Symptoms: Drug-Induced Extrapyramidal Symptoms Scale. Tokyo: Seiwa Shoten Publishers, Inc.; 2009.Google Scholar
de Greef, R, Maloney, A, Olsson-Gisleskog, P, et al. Dopamine D2 occupancy as a biomarker for antipsychotics: quantifying the relationship with efficacy and extrapyramidal symptoms. AAPS J. 2011;13(1):121–130.CrossRefGoogle ScholarPubMed
Shahid, M, Walker, GB, Zorn, SH, et al. Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. J Psychopharmacol. 2009;23(1):65–73.CrossRefGoogle ScholarPubMed
Abrams, P, Andersson, KE, Buccafusco, JJ, et al. Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder. Br J Pharmacol. 2006;148:565–578.CrossRefGoogle ScholarPubMed
Uchida, H, Suzuki, T, Takeuchi, H, et al. Low-dose vs standard dose of antipsychotics for relapse prevention in schizophrenia: meta-analysis. Schizophr Bull. 2011;37(4):788–799.CrossRefGoogle ScholarPubMed
WHO. Collaborating centre for drug statistics methodology 2009. http://www.whocc.no/atcddd/. Accessed June 10, 2020.Google Scholar
Lang, FU, Kösters, M, Lang, S, et al. Psychopathological long-term outcome of schizophrenia – a review. Acta Psychiatrica Scand. 2013;127(3):173–182.CrossRefGoogle ScholarPubMed
Harrigan, SM, McGorry, PD, Krstev, H. Does treatment delay in first-episode psychosis really matter? Psychol Med. 2003;33:97–110.CrossRefGoogle ScholarPubMed
Marshall, M, Lewis, S, Lockwood, A, et al. Association between duration of untreated psychosis and outcome in cohorts of first-episode patients: a systemic review. Arch Gen Psychiatry. 2005;62:975–983.CrossRefGoogle Scholar
Perkins, DO, Gu, H, Boteva, K, et al. Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: a critical review and meta-analysis. Am J Psychiatry. 2005;162(10):1785–1804.CrossRefGoogle ScholarPubMed
Soehner, AM, Kaplan, KA, Harvey, AG. Insomnia comorbid to sever psychiatric illness. Sleep Med Clin. 2013;8(3):361–371.CrossRefGoogle Scholar
Stepanova, E, Grant, B, Findling, RL. Asenapine treatment in pediatric patients with bipolar I disorder or schizophrenia: a review. Paediatr Drugs. 2018;20(2):121–134.CrossRefGoogle ScholarPubMed
Ng, J, Papandreou, A, Heales, SJ, et al. Monoamine neurotransmitter disorders—clinical advances and future perspectives. Nat Rev Neurol. 2015;11(10):567–584.CrossRefGoogle ScholarPubMed
Volavka, J, Czobor, P, Sheitman, B, et al. Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. Am J Psychiatry. 2002;159(2):255–262.CrossRefGoogle ScholarPubMed
Tollefson, GD, Birkett, MA, Kiesler, GM, et al. Double-blind comparison of olanzapine vs clozapine in schizophrenic patients clinically eligible for treatment with clozapine. Biol Psychiatry. 2002;49(1):52–63.CrossRefGoogle Scholar
Meltzer, HY, Bobo, WV, Roy, A, et al. A randomized, double-blind comparison of clozapine and high-dose olanzapine in treatment-resistant patients with schizophrenia. J Clin Psychiatry. 2008;69(2):274–285.CrossRefGoogle ScholarPubMed
Ogyu, K, Noda, Y, Yoshida, K, et al. Early improvements of individual symptoms as predictor of treatment response to asenapine in patients with schizophrenia. Neuropsychopharmacol Rep. 2020;40(2):138–149.CrossRefGoogle ScholarPubMed
Rampino, A, Marakhovskaia, A, Soares-Silva, T, et al. Antipsychotic drug responsiveness and dopamine receptor signaling; old players and new prospects. Front Psychiatry. 2019;9:702. doi:10.3389/fpsyt.2018.00702.CrossRefGoogle ScholarPubMed
Scordo, MG, Spina, E. Cytochrome P450 polymorphism and response to antipsychotic therapy. Pharmacogenomics. 2002;3(2):201–218.CrossRefGoogle ScholarPubMed
McCutcheon, RA, Pillinger, T, Mizuno, Y, et al. The efficacy and heterogeneity of antipsychotic response in schizophrenia: a meta-analysis. Mol Psychiatry. doi:10.1038/s41380-019-0502-5. Epub ahead of print.CrossRefGoogle Scholar
Chen, J, Patil, KR, Weis, S, et al. Neurobiological divergence of the positive and negative schizophrenia subtypes identified on a new factor structure of psychopathology using non-negative factorization: an international machine learning study. Biol Psychiatry. 2020;87:282–293.CrossRefGoogle ScholarPubMed
Keil, J, Roa Romero, Y, Balz, J, et al. Positive and negative symptoms in schizophrenia relate to distinct oscillatory signatures of sensory gating. Front Hum Neurosci. 2016;10:162. doi:10.3389/fnhum.2016.00104.Google ScholarPubMed
Supplementary material: File

Takekita et al. supplementary material

Figure S1

Download Takekita et al. supplementary material(File)
File 22.2 KB